Lipoprotein, apolipoprotein (ape), and hormone levels were measured in 12 healthy women over three consecutive menstrual cycles; one free-living and two under controlled dietary conditions. Serum hormone levels were measured to identify menstrual cycle phases (menses, early follicular, late follicular, and midluteal). After stabilization for one cycle on the controlled diet, ANOVA modeling of the second controlled-diet cycle revealed that low-density lipoprotein (LDL) cholesterol levels in the midluteal phase were significantly lower (by 7%) than in the early follicular phase. High-density lipoprotein (HDL) cholesterol levels during the late follicular phase were higher (by 6%) than menses levels. Differences in the HDL-cholesterol and apoA-I fluctuations resulted in a higher proportion of HDL-cholesterol to apoA-I during the late follicular phase than that during the menses phase. The ratios of LDL cholesterolHDL cholesterol and apoB/apoA-I in the early follicular phase were greater by 5.6% and 6.0%, respectively, than those in the midluteal phase. Fluctuations in total cholesterol, triglyceride, apoA-I, and apoB did not reach significance. Thus, the cyclic fluctuations of LDL and HDL cholesterol need to k considered in the screening and medical monitoring of women with borderline lipoprotein levels, as well as in the design and the interpretation of results of studies involving premenopausal women. (J Clin Endowinol Metab 81: 3599-3603, 1996) 0 RAL ESTROGEN and progestogen administration in pre-and postmenopausal women have pronounced effects on lipoprotein levels. Estrogens decrease levels of low-density lipoprotein (LDL) cholesterol and apolipoprotein (apo) B, and increase high-density lipoprotein (HDL) cholesterol and apoA-I (1, 2). These changes are associated with a decreased risk of cardiovascular disease (3). On the other hand, progestogens tend to reverse these favorable effects (1, 4) .
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Among the studies that have examined fluctuations of lipoprotein levels by phase of the menstrual cycle, Kim and Kalkhoff (5) were the first to report changes in apolipoprotein as well as lipoprotein levels in the free-living (FL) state. Total and LDL cholesterol and apoB levels during the luteal phase were lo-25% lower than during the follicular phase. Results from subsequent studies have been inconsistent. Some investigators have reported that total cholesterol, LDL cholesterol, or apoB levels during the luteal phase were lower than levels during the follicular phase (5-lo), whereas others found either no change or fluctuations that did not reach significance (1 l-14). Follicular HDL cholesterol and / or apoA-I levels were reportedly higher than menses (MEN) levels in some investigations (7, 10, 13, 15, 16) , but not others (8, 9, 12, 14) . Finally, significant elevations in triglycerides have been reported during midcycle in some studies (6, 8, 12) , but not in others (5, 7, 9, 11) .
Only a few studies (10,15) have measured hormone and lipid levels with sufficient frequency to adequately assess lipoprotein levels by phase of the menstrual cycle. Further, diet is known to affect lipoprotein levels. Thus, it is important to examine changes during the menstrual cycle under controlled dietary (CD) conditions. In one CD study (6), significant fluctuations were found in total and HDL cholesterol, and changes in triglyceride levels appeared to be dependent on the level of fat in the diet. In a second CD study, fluctuations in total and lipoprotein cholesterol failed to reach significance, but triglycerides were increased during the ovulatory phase (12). Thus, the large majority of the research has not been conducted under CD conditions nor with frequent blood draws to identify menstrual cycle phase.
The current study was designed with frequent measurements of serum hormone levels to precisely identify menstrual cycle phase, and concomitant lipid / apolipoprotein measurements during one menstrual cycle in the FL state followed by two cycles under CD conditions. The first two study cycles were designed to confirm that participants experienced an ovulatory cycle in the FL state, and place the participants on a CD regimen for one cycle (CDl) 
Results

Subject characteristics
The 12 study subjects had a mean age of 27 2 3 yr, body mass index of 21 2 2, average menstrual cycle of 27 ? 2 days, and an average educational level of 13 ? 2 yr.
The average reported macronutrient levels during the FL cycle were 33% of the calories as fat (11.1% saturated) with a I':S ratio of 0.60, compared with 36% fat and a PS ratio of 0.53 during the CD1 and CD2 cycles.
Hormone levels
Serum estradiol levels during the LF phase were 6-fold higher than those during the EF phase and were reversed approximately 50% in the LUT phase (Table 1 ). Progesterone concentrations increased over ll-fold from the LF to LUT phase, and the peak LH concentration was 84 mIU/mL at the LH surge.
Lipoprotein lap0 levels
In the LUT phase of CD2, LDL cholesterol concentrations were 7% lower than the EF levels ( Table 2 ). ApoB levels closely followed those of LDL cholesterol, but the fluctuations did not reach significance. Similar patterns and mag- nitude of change were found during the FL and CD1 cycles; both shifted to higher levels after initiation of the CD (Fig. 1) . Concentrations at the MEN phase during the CD2 were used as a reference because any diet-induced influences on lipoprotein levels would be minimal. The HDL cholesterol level in the LF phase was 6% higher than in the MEN phase (Table 2 ). In contrast, peak apoA-I levels appeared in the LUT phase. However, the changes were smaller than those of HDL cholesterol and did not reach statistical significance. The differences in the HDL cholesterol and apoA-I patterns ( Fig. 2 ) resulted in significant cyclic changes in the ratio of HDL cholesterol to apoA-I ( Table 2 ). The ratio peaked during the LF phase and was lowest during the MEN phase. A similar significant change appeared in the CD1 cycle (not shown). Ratios of LDL cholesterol/HDL cholesterol and apoB / apoA-I during the EF phase were significantly greater than those during the LUT phase.
Discussion
This two-cycle CD study was designed to assess hormone and lipoprotein changes across the menstrual cycle while minimizing possible effects of dietary fat on cyclic fluctuations in lipoprotein levels (6,25), and allowing sufficient time for the lipoprotein levels to stabilize at a new steady state (26). Hormone levels were frequently analyzed to precisely identify the phases of the cycle. Results from this study demonstrate cyclic fluctuations in lipoprotein levels under these stabilized CD conditions. After stabilization, LDL cholesterol (and apoB) peaked during the EF phase and were at their lowest levels during the LUT phase. Thus, levels of both LDL cholesterol and apoB were at a minimum when estrogen and progesterone levels were high. On the other hand, HDL cholesterol levels were highest in the LF phase when estrogen levels were at a maximum. Changes in apoA-I levels were markedly smaller than those of HDL, and levels peaked in the LUT phase.
The cyclic change in LDL cholesterol is in accord with prior studies (5-10). An identical fluctuation in LDL cholesterol (0.1 mmol/ L) was reported in one of the two CD studies (12). Similar fluctuations in HDL cholesterol (0.05-0.10 mmol/L) were found in both studies (6, 12), but fluctuations in LDL and HDL cholesterol did not reach significance in one of the studies (12). Possible reasons for not achieving significance are: 1) variable recoveries of LDL in ultracentrifugation fractions, 2) single samples were analyzed from each of the phases, 3) day-to-day variations in analyses, and 4) the SES were double those in the current study.
The suppression of LDL levels during the phases when estradiol levels are high is consistent with the established decrease in LDL levels by exogenous unopposed estrogens (1, 2). Presumably, the decrease in LDL could be attributed to an estrogen-induced increase in hepatic LDL-receptor activity during the LF and LUT phases (27). In addition, the demands of growth of the endometrial lining and steroid hormone synthesis during the follicular and LUT phases of the cycle could contribute to the decrease in LDL during these phases. The LDL receptors of the corpus luteum peak during the LUT phase (28), and granulosa cells reportedly assimilate LDL for progesterone synthesis (29). A reported rate of progesterone secretion of 40 mg/day (0.12 mmol/ day) by the corpus luteurn (30) is nearly one-half of the reduction in LDL cholesterol (assuming a 2.7 liter plasma volume) during the LUT phase.
Differences in the HDL cholesterol and apoA-I fluctuations resulted in a higher ratio of HDL cholesterol to apoA-I in the LF phase, indicative of an alteration in HDL composition. Azogui et ul. (13) recently reported an increased HDL cholesterol/apoA-I ratio at day 23 after MEN (midluteal) compared with the ratio at days 1 (EF) and 14 (LF) of the cycle. The study was in a FL population, and the menstrual cycle phases were not clearly described to assure that days 14 and 23 truly reflected the respective LF and LUT phases. These methodological issues may have contributed to the apparent discrepancy with the current findings. The LF increase in HDL cholesterol and in the proportion of HDL cholesterol to apoA-I is likely caused by an increase in the HDLZa subfraction (31), and thus, an increase in the HDL lipid content after midcycle. These changes may be caused by a decrease in hepatic lipoprotein lipase activity during the LUT phase of the cycle (32), resulting in a decrease in the removal of cholesterol from HDL and in the conversion of HDLZ to HDLs.
In summary, under CD conditions and with precise identification of phases of the menstrual cycle, significant cyclic fluctuations were found in LDL and HDL cholesterol, the ratios of LDL cholesterol/HDL cholesterol and apoA-I/ apoB, and the cholesterol content of HDL. The cyclic fluctuations in lipoprotein levels need to be taken into consideration in the screening and medical monitoring of lipoprotein levels in premenopausal women. Further, failure to take these cyclic changes into account could confound the results of studies involving premenopausal women. Main activities will be Socratic debates about polemic subjects, meet-the-professor sessions, and symposia. Each day will be dedicated to special fields in Endocrinology.
About 2,500 physicians are expected to attend. 
